SI-BONE: Breakthrough Pipeline and DRG Tailwinds Set Up a New Growth Phase
A Catalyst-Laden Quarter
SI-BONE has been building a platform around patients with compromised bone, and the second quarter of 2026 demonstrated that the strategy is compounding. On the call, CEO Laura Francis reiterated the company's focus: “We submitted the 510(k) application for our third technology with breakthrough device designation.” — Laura Francis, Chief Executive Officer · 2026-08-03 That device, the first designed for use outside the pelvis, targets a recognized failure point in complex spine procedures and can be used independently or with Granite. Management expects clearance in the fourth quarter, potentially as early as October, and plans a phased commercial launch.
The reimbursement backdrop also turned decisively positive. The company highlighted new DRGs for complex spinal fusion procedures that could increase hospital payment by up to $50,000 per Granite case, while proposed CMS changes would raise reimbursement for SI joint fusion across hospital outpatient, ASC, and OBL settings. This is a meaningful shift: “CMS has proposed increasing hospital outpatient reimbursement by approximately $2,300 to more than $20,000.” — Laura Francis, Chief Executive Officer · 2026-08-03 This isn't just a small adjustment—it changes the economics of treating this patient population and removes a key barrier to adoption.
The new family of DRGs for complex spinal fusion procedures, including procedures incorporating Granite, is encouraging.
These new DRGs are particularly attractive because they are more durable than transitional pass-through payments and should also influence commercial payers. The company believes they will support the long-term adoption of Granite and the upcoming breakthrough device.
Financial Momentum and Operating Leverage
The strategy is translating into accelerating profitability. CFO Anshul Maheshwari noted: “Adjusted EBITDA improved 178% to $2.8 million, representing an adjusted EBITDA margin of approximately 5.1%.” — Anshul Maheshwari, Chief Financial Officer · 2026-08-03 Revenue grew 15.2% to $56 million during the quarter, while operating expenses increased just 7.7%, producing strong operating leverage. The company raised the low end of its full-year revenue guidance to $231-$233 million.
The revenue trajectory is well-established. The fundamentals series shows revenue has grown from $12M in 2017 to over $53M in the latest filed quarter, and management reported $56M for Q2. Gross margin has held around 79-80% despite new product launches, a testament to the asset-light model. With $145.9 million in cash and a path to consistent free cash flow, the balance sheet supports the innovation pipeline.
Physician Engagement and Commercial Expansion
Beyond product and reimbursement catalysts, the company's commercial engine is humming. The number of unique physicians performing procedures reached 1,715 in the quarter, up 19% year over year, with double-digit growth across all call points. “It's broad-based, actually,” — Laura Francis, Chief Executive Officer · 2026-08-03 Laura noted, referring to procedure volume growth across SI joint fusion, pelvic fixation, and pelvic trauma. The company added territories and expects to exit the year with nearly 100 quota-carrying territory managers, up from 93.
The physician engagement strategy has been a consistent theme. On the prior quarter's call, Laura described the opportunity: “We said we will have a filing in early third quarter and expect the product to launch sometime in the fourth quarter.” — Laura Francis, Chief Executive Officer (CEO) · 2026-05-11 That realization on schedule reinforces confidence in execution. As she noted back in Q3 2025, “Physician density is actually a very important focus point for us.” — Laura A. Francis, CEO · 2025-11-10
Management is focused on procedure volumes and physician density, with physicians active in both quarters averaging three times the case volume of new physicians. With a hybrid commercial model and the Smith+Nephew partnership expanding trauma access, the company looks well-positioned to absorb the new launches. Shares have rallied 55% in the past three months, reflecting growing confidence in these catalysts.
International revenue also accelerated, growing 26% to $2.8 million, led by demand for TORQ and TNT. Management is evaluating additional markets and expects the international segment to become a durable contributor. Longer-term, the company's pipeline includes two additional solutions targeting design freeze, with commercialization over the next 18 months, and an exploration of AI-driven procedure enablement. As Laura summarized: “We have a lot of catalysts that we're talking here that are going to drive these procedure volumes.” — Laura Francis, Chief Executive Officer · 2026-08-03